IP Verse

Cell Line Expressing Single Chain Factor Viii Polypeptides And Uses Thereof - EP2870250

The patent EP2870250 was granted to Biogen Idec MA on Jun 29, 2022. The application was originally filed on Jul 5, 2013 under application number EP13813225A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2870250

BIOGEN IDEC MA
Application Number
EP13813225A
Filing Date
Jul 5, 2013
Status
Patent Maintained As Amended
May 27, 2022
Grant Date
Jun 29, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

EUROPEAN OPPOSITIONSJan 18, 2019ELKINGTON AND FIFEADMISSIBLE
FH SERVICESJan 17, 2019BECK GREENERADMISSIBLE

Patent Citations (31) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP2173890
DESCRIPTIONUS2003235536
DESCRIPTIONUS2010292130
DESCRIPTIONUS6030613
DESCRIPTIONUS6086875
DESCRIPTIONUS6485726
DESCRIPTIONWO03077834
DESCRIPTIONWO2008155134
INTERNATIONAL-SEARCH-REPORTWO2011041770
INTERNATIONAL-SEARCH-REPORTWO2012006623
INTERNATIONAL-SEARCH-REPORTWO8707144
OPPOSITIONEP0294910
OPPOSITIONUS2011065114
OPPOSITIONUS7041635
OPPOSITIONUS7432103
OPPOSITIONWO0170968
OPPOSITIONWO2004067566
OPPOSITIONWO2011041770
OPPOSITIONWO2011069164
OPPOSITIONWO2012006623
OPPOSITIONWO2013009627
OPPOSITIONWO2013106787
OPPOSITIONWO2014008480
OPPOSITIONWO2014011819
OPPOSITIONWO2014210547
OPPOSITIONWO2014210558
OPPOSITIONWO8707144
OPPOSITIONWO8800831
OPPOSITIONWO8805825
OPPOSITIONWO9706251
SEARCHWO2013106787

Non-Patent Literature (NPL) Citations (47) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- "Antibody Engineering: A Practical Approach", Practical Approach Series, McCafferty, (19960000), vol. 169-
DESCRIPTION- BAI et al., Proc. Natl. Acad. Sci. USA, (20050000), vol. 102, pages 7292 - 7296-
DESCRIPTION- BRANDSMA et al., Biotechnol. Adv., (20110000), vol. 29, pages 230 - 238-
DESCRIPTION- COONEY et al., Science, (19880000), vol. 241, page 456-
DESCRIPTION- DERVAN et al., Science, (19910000), vol. 251, page 1300-
DESCRIPTION- DOBELI et al., J Biotechnology, (19880000), vol. 7, pages 199 - 216-
DESCRIPTION- FATOUROS et al., Intern. J. Pharm., (19970000), vol. 155, no. 1, pages 121 - 131-
DESCRIPTION- "GenBank", Database accession no. M12530-
DESCRIPTION- "GenBank", Database accession no. NM001063-
DESCRIPTION- "GenBank", Database accession no. S95936-
DESCRIPTION- "GenBank", Database accession no. XM002793-
DESCRIPTION- "GenBank", Database accession no. XM039845-
DESCRIPTION- "GenBank", Database accession no. XM 039847-
DESCRIPTION- ISRAEL et al., Immunology, (19970000), vol. 92, page 69-
DESCRIPTION- KIM et al., J Pharmacol. Exp. Ther., (20100000), vol. 334, pages 682 - 692-
DESCRIPTION- LEE et al., Nucleic Acids Research, (19790000), vol. 6, page 3073-
DESCRIPTION- LI et al., Trends Pharmacol. Sci., (20020000), vol. 23, pages 206 - 209-
DESCRIPTION- MEI et al., Mol. Biotechnol., (20060000), vol. 34, no. 2, pages 165 - 78-
DESCRIPTION- OKANO, J. Neurochem, (19910000), vol. 56, page 560-
DESCRIPTION- PAUL, S.; HUMANA PR, "Antibody Engineering Protocols", Methods in Molecular Biology, (19960000), vol. 510-
DESCRIPTION- RON et al., J Biol. Chem., (19930000), vol. 268, pages 2984 - 2988-
DESCRIPTION- SOMMERMEYER et al., Krankenhauspharmazie, (19870000), vol. 8, pages 271 - 278-
DESCRIPTION- STORY et al., J. Exp. Med., (19940000), vol. 180, page 2377-
DESCRIPTION- TRUSSELET et al., Bioconjugate Chem., (20090000), vol. 20, pages 2286 - 2292-
DESCRIPTION- WAKABAYASHI et al., JBC, (20040000), vol. 279, no. 13, pages 12677 - 12684-
DESCRIPTION- WANG et al., J. Controlled Release, (20110000), vol. 155, pages 386 - 392-
DESCRIPTION- WEIDLER et al., Arzneim.-Forschung/Drug Res., (19910000), vol. 41, pages 494 - 498-
OPPOSITION- Bihoreau et al, Biochem. J., (19910000), vol. 277, pages 23 - 31-
OPPOSITION- BIHOREAU et al., "STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF FACTOR VIII-DELTAII, A NEW RECOMBINANT FACTOR VIII LACKING MOST OF THE B-DOMAIN", Biochem. J., (19910000), vol. 277, pages 23 - 31, XP008022185-
OPPOSITION- Buyue et al, "A Single Chain Variant of Factor VIII Fusion Protein Retains Normal In Vivo Efficacy but Exhibits Altered In Vitro Activity", PLOS ONE, (20140000), vol. 9, no. 11-
OPPOSITION- Hopkins et al, Physiology, Acid Base Balance-
OPPOSITION- Krishnan et al, Eur. J. Biochem., (19910000), vol. 195, pages 637 - 644-
OPPOSITION- Pipe, S.W., Haemophilia, (20090000), vol. 15, pages 1187 - 1196-
OPPOSITION- "Stable Cell Lines", Cell Transfection - Biology Research for Scientists-
OPPOSITION- PIPE, S.W., "Functional roles of the factor VIII B domain", Haemophilia, (20090000), vol. 15, pages 1187 - 1196, XP002572338
OPPOSITION- KRISHNAN et al., "Thrombin cleavage analysis of a novel antihaemophilic factor variant, factor VIII dII", Eur. J. Biochem., (19910000), vol. 195, pages 637 - 644, XP002992596
OPPOSITION- BUYUE et al., "A Single Chain Variant of Factor VIII Fc Fusion Protein Retains Normal In Vivo Efficacy but Exhibits Altered In Vitro Activity", PLOS ONE, (20140000), vol. 9, no. 11, XP002752089
SEARCH- GREENE TESHELL K ET AL, "Understanding Ectopically Expressed Factor VIII (F8) in Megakaryocytes: Implications for Optimum Platelet-Delivered F8 Activity for Gene Therapy.", BLOOD, & 52ND ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); ORLANDO, FL, USA; DECEMBER 04 -07, 2010, (201011), vol. 116, no. 21, page 909, XP009187650 [Y] 1-13 * abstract *-
SEARCH- JOSHUA I SINER ET AL, "Bioengineering Factor VIII B-Domain Sequences Improves Function and Efficacy in Hemophilia A Models", BLOOD; 54TH ANNUAL MEETING AND EXPOSITION OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); ATLANTA, GA, USA; DECEMBER 08 -11, 2012, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 120, no. 21, ISSN 0006-4971, (20121101), URL: https://ash.confex.com/ash/2012/webprogram/Paper49627.html, XP002696553 [IP] 1-13 * abstract *-
SEARCH- DONATH MARIE-JOSE S H ET AL, "Characterization of des-(741-1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa", BIOCHEMICAL JOURNAL, PORTLAND PRESS LTD, GB, (19951115), vol. 312, no. 1, ISSN 0264-6021, pages 49 - 55, XP009155492 [Y] 1-13 * abstract * * page 51, column l, paragraph 4 *
SEARCH- R. M. CAMIRE ET AL, "The molecular basis of factor V and VIII procofactor activation", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, (20091201), vol. 7, no. 12, doi:10.1111/j.1538-7836.2009.03622.x, ISSN 1538-7933, pages 1951 - 1961, XP055173186 [A] 1-13 * abstract *
SEARCH- R. T. PETERS ET AL, "Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, (20130127), vol. 11, no. 1, doi:10.1111/jth.12076, ISSN 1538-7933, pages 132 - 141, XP055092640 [IP] 1-13 * abstract * * page 143, column r, paragraph 4; figure 2A *
SEARCH- DENISE E SABATINO ET AL, "Recombinant Canine B-Domain Deleted FVIII Exhibits High Specific Activity and is Safe in the Canine Hemophilia A Model", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 114, no. 20, doi:10.1182/BLOOD-2009-05-220327, ISSN 0006-4971, (20090921), pages 4562 - 4565, (20090921), XP008155594 [Y] 1-13 * abstract * * page 4562 - page 4563, column l, line 5 *
SEARCH- J. A. DUMONT ET AL, "Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs", BLOOD, (20120329), vol. 119, no. 13, doi:10.1182/blood-2011-08-367813, ISSN 0006-4971, pages 3024 - 3030, XP055065095 [A] 1-13 * abstract * * page 3026, column r, paragraph 1 *
SEARCH- JERRY S POWELL ET AL, "Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 119, no. 13, doi:10.1182/BLOOD-2011-09-382846, ISSN 0006-4971, (20120329), pages 3031 - 3037, URL: http://www.bloodjournal.org/content/119/13/3031?sso-checked=1, XP002727554 [A] 1-13 * abstract * * page 3035, column r, paragraph 2 - page 3036, column r, paragraph 1 *
SEARCH- J. I. SINER ET AL, "Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype", BLOOD, (20130131), vol. 121, no. 21, doi:10.1182/blood-2012-10-464164, ISSN 0006-4971, pages 4396 - 4403, XP055100144 [IP] 1-13 * abstract * * page 4396 - page 4397, column l, paragraph 1 *
SEARCH- YANG BUYUE ET AL, "A Single Chain Variant of Factor VIII Fc Fusion Protein Retains Normal In Vivo Efficacy but Exhibits Altered In Vitro Activity", PLOS ONE, (201411), vol. 9, no. 11, XP002752089 [T] * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents